These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 9612891)

  • 21. Application of GEE procedures for sample size calculations in repeated measures experiments.
    Rochon J
    Stat Med; 1998 Jul; 17(14):1643-58. PubMed ID: 9699236
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multiple imputation compared with some informative dropout procedures in the estimation and comparison of rates of change in longitudinal clinical trials with dropouts.
    Ali MW; Siddiqui O
    J Biopharm Stat; 2000 May; 10(2):165-81. PubMed ID: 10803723
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Selection through patient dropouts in therapeutic series].
    Uberla K
    Methods Inf Med Suppl; 1976; 9():37-45. PubMed ID: 1078448
    [No Abstract]   [Full Text] [Related]  

  • 24. Corrected profile likelihood confidence interval for binomial paired incomplete data.
    Pradhan V; Menon S; Das U
    Pharm Stat; 2013; 12(1):48-58. PubMed ID: 23296487
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Baseline observation carry forward: reasoning, properties, and practical issues.
    Shao J; Jordan DC; Pritchett YL
    J Biopharm Stat; 2009 Jul; 19(4):672-84. PubMed ID: 20183433
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Modeling longitudinal count data with dropouts.
    Alosh M
    Pharm Stat; 2010; 9(1):35-45. PubMed ID: 19191272
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Still waiting on watchful waiting: clinical trials test surveillance.
    Bankhead C
    J Natl Cancer Inst; 2003 Nov; 95(22):1657-9. PubMed ID: 14625256
    [No Abstract]   [Full Text] [Related]  

  • 28. Assessing missing data assumptions in longitudinal studies: an example using a smoking cessation trial.
    Yang X; Shoptaw S
    Drug Alcohol Depend; 2005 Mar; 77(3):213-25. PubMed ID: 15734221
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Including multiple imputation in a sensitivity analysis for clinical trials with treatment failures.
    Shaffer ML; Chinchilli VM
    Contemp Clin Trials; 2007 Feb; 28(2):130-7. PubMed ID: 16877049
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A graphical assessment of the potential impact of losses to follow-up on the validity of study results. The Terry Beirn Community Programs for Clinical Research on AIDS.
    Matts JP; Launer CA; Nelson ET; Miller C; Dain B
    Stat Med; 1997 Sep; 16(17):1943-54. PubMed ID: 9304765
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A conditional analysis for two-treatment multiple-period crossover designs with binomial or poisson outcomes and subjects who drop out.
    McKnight B; Van den Eeden SK
    Stat Med; 1993 May; 12(9):825-34. PubMed ID: 8327802
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sensitivity analyses for partially observed recurrent event data.
    Akacha M; Ogundimu EO
    Pharm Stat; 2016; 15(1):4-14. PubMed ID: 26540016
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Use of statistical analysis in open extension studies.
    Yazici Y; Yazici H
    J Rheumatol; 2006 Feb; 33(2):437; author reply 437-8. PubMed ID: 16465682
    [No Abstract]   [Full Text] [Related]  

  • 34. 'Supramalleolar orthoses and postural stability in children with Down syndrome--Martin replies'.
    Martin K
    Dev Med Child Neurol; 2005 Jan; 47(1):71. PubMed ID: 15686293
    [No Abstract]   [Full Text] [Related]  

  • 35. Assessment of relative improvement due to weights within generalized estimating equations framework for incomplete clinical trials data.
    Demirtas H
    J Biopharm Stat; 2004 Nov; 14(4):1085-98. PubMed ID: 15587981
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The statistician's role in the prevention of missing data.
    Hughes S; Harris J; Flack N; Cuffe RL
    Pharm Stat; 2012; 11(5):410-6. PubMed ID: 22807372
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Multiple imputation for model checking: completed-data plots with missing and latent data.
    Gelman A; Van Mechelen I; Verbeke G; Heitjan DF; Meulders M
    Biometrics; 2005 Mar; 61(1):74-85. PubMed ID: 15737080
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Commentary on Smolkowski et al. (2010): why is it important to assume that non-responders in tobacco cessation trials have relapsed?
    Hajek P; West R
    Addiction; 2010 Jun; 105(6):1016-7. PubMed ID: 20659061
    [No Abstract]   [Full Text] [Related]  

  • 39. Dropout rates for intent-to-treat and per protocol analyses.
    Stewart WC; Jackson AL; Jenkins JN
    Am J Ophthalmol; 2004 Apr; 137(4):639-45. PubMed ID: 15059702
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Bayesian framework for intent-to-treat analysis with missing data.
    Kleinman KP; Ibrahim JG; Laird NM
    Biometrics; 1998 Mar; 54(1):265-78. PubMed ID: 9544521
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.